DEF: LeMaitre Vascular Sets Date for 2025 Annual Stockholders Meeting, Outlines Proposals

LeMaitre Vascular will hold its 2025 Annual Meeting of Stockholders on June 2, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

• LeMaitre Vascular, Inc. will hold its 2025 Annual Meeting of Stockholders on Monday, June 2, 2025, at 10:00 a.m. EDT at its Burlington, Massachusetts offices.
• Stockholders of record as of April 8, 2025, are entitled to vote.
• The meeting's agenda includes the election of three Class I directors, an advisory vote on executive compensation, a vote on the frequency of future executive compensation votes, and the ratification of Grant Thornton LLP as the independent auditor for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR all director nominees, FOR Proposal 2 (executive compensation), every THREE YEARS for Proposal 3 (frequency of say-on-pay votes), and FOR Proposal 4 (auditor ratification).
• The company is taking advantage of SEC rules allowing electronic delivery of proxy materials, reducing environmental impact and costs.
• At the close of business on the Record Date, there were 22,594,362 shares of our common stock outstanding and entitled to vote at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the agenda and procedures for the annual meeting. The financial results presented are positive, contributing to a moderately positive sentiment.

Positives

• The company is utilizing electronic delivery of proxy materials to reduce environmental impact and costs.
• The Board of Directors is actively engaged in risk oversight, including financial, strategic, operational, cybersecurity, ESG, and legal/regulatory risks.
• The company has a Compensation Recovery Policy (Clawback Policy) in place to recover erroneously awarded incentive-based compensation from executive officers under certain conditions.
• The Board has determined that five directors are independent: Lawrence J. Jasinski, John J. O'Connor, Bridget A. Ross, John A. Roush, and Martha Shadan.
• The company's executive compensation program is designed to align executive interests with those of stockholders.

Negatives

• At the 2024 Annual Meeting, Larry Jasinski received fewer votes FOR his election than WITHHELD votes, requiring the Board to address his resignation offer, though it was ultimately rejected.

Risks

• The document mentions areas of material risk to the Company, including financial, strategic, operational, cybersecurity, environmental, social and governance (ESG), and legal and regulatory.
• The document mentions that the Board believed that the outcome of the vote related principally to stockholder displeasure with our Boards lack of racial and ethnic diversity.

Future Outlook

The document does not contain specific forward-looking statements beyond the scheduling of the annual meeting and the proposals to be voted on.

Management Comments

• George W. LeMaitre, Chairman and Chief Executive Officer, expresses gratitude to stockholders and encourages their participation in the Annual Meeting.

Industry Context

The document provides limited direct industry context, but the peer group used for compensation benchmarking includes Angiodynamics, Anika Therapeutics, Artivion, Atricure, Atrion Corporation, AxoGen, CONMED Inc., Greatbatch Inc., Inari Medical Inc., Integra LifeSciences Inc., Merit Medical Systems, Inc., Orthofix Medical Inc., Penumbra Inc., ShockWave Medical Inc., Silk Road Medical Inc., Surmodics, Inc., Tactile Systems Technology, Inc., and TransMedics Group, Inc., indicating the competitive landscape for talent and performance.

Comparison to Industry Standards

• The compensation of the top three NEOs was benchmarked against a peer group of 18 public medical device companies.
• The company was in the 25th percentile for revenue, the 66th percentile for operating income, the 50th percentile for market capitalization, and the 25th percentile for employee population compared to its peer group.
• NEO cash compensation was targeted to the 37th percentile of the benchmarks.
• Equity awards were granted at or below the 37th percentile of the market data.

Management Changes

Stakeholder Impact

• Stockholders are invited to participate in the Annual Meeting and vote on key proposals.
• The outcome of the votes on executive compensation and the frequency of future votes will influence the company's compensation policies.
• The election of directors will shape the composition of the Board of Directors and its oversight of the company.
• Employees are affected by the company's compensation policies and practices.
• The company's financial performance impacts its stakeholders, including stockholders, employees, and customers.

Next Steps

• Stockholders should review the proxy materials and vote their shares by proxy or in person at the Annual Meeting.
• The Board of Directors will consider the outcome of the advisory votes on executive compensation and the frequency of future votes.
• The Audit Committee will continue to oversee the company's accounting and financial reporting processes.
• The Compensation Committee will continue to review and determine executive compensation.
• The Nominating and Corporate Governance Committee will continue to review and recommend director nominees.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Grant Thornton, Auditor Ratification, Corporate Governance, LeMaitre Vascular